Aurobindo Pharma Acquisition Worth ₹146.4 Cr

Aurobindo Pharma Board Meeting Date

Aurobindo Pharma's board meets 4 November 2026 to consider Q2 and half-year results and a possible interim dividend. Trading window stays closed until 6 November.

Aurobindo Pharma Other Announcement

Aurobindo Pharma Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as mandated by SEBI regulations.

Aurobindo Pharma Business Update

Aurobindo Pharma received USFDA final approval for Perampanel Tablets in multiple strengths. The product will be manufactured by its subsidiary and launched in Q3FY27.

Aurobindo Pharma Acquisition

Aurobindo Pharma's subsidiary, Apitoria Pharma, has completed the acquisition of the Contract Research Services business of A1 Biochem Group. The deal integrates CRO capabilities into Apitoria's operations.

Aurobindo Pharma Merger & Restructuring Worth ₹33.8 Cr

Aurobindo Pharma's subsidiary, Apitoria Pharma, completed a 20% stake dilution in A1 Biochem Labs. Dr. Rajendra Gadikota subscribed to securities worth ₹33.80 Crore.

Value

₹33.80 Cr

Aurobindo Pharma Product Launch

Acrotech Biopharma launched ADQUEY (difamilast 1% ointment) in the U.S. and established a dedicated dermatology business unit to support this market entry.

MosChip Technologies Acquisition Worth ₹266.7 Cr

MosChip will acquire Vayavya Labs for Rs.266.71 Crore in cash and shares. Completion awaits RBI and exchange approvals and shareholder approval of a preferential issue.

Value

₹266.7 Cr

Execution

Within 15 days of the later of receipt of all requisite approvals or shareholder approval of the preferential issue to VLPL sellers

Hexaware Technologies Acquisition

Hexaware Technologies announced amalgamation of two wholly owned step-down subsidiaries into its Canadian subsidiary. No cash consideration is involved, and the merger is internal group restructuring.

Zensar Technologies Acquisition

Zensar's board approved merging its wholly owned subsidiary M3bi India into the parent. No consideration or share issuance is involved, and NCLT sanction is pending.

ICICI Lombard General Insurance Company Acquisition Worth ₹172 Cr

ICICI Lombard disclosed that it acquired Rs.172 Crore of State Bank of India shares on October 28, 2026, in its ordinary-course investment function. Its cumulative holding in SBI is now 0.02%.

Value

₹172.0 Cr

Execution

Investment made in multiple tranches over a period of time

Emkay Global Financial Services Acquisition Worth ₹30 Cr

Emkay Global will buy Emkay Capital Private Limited for Rs 30 Crore in cash. The related-party deal is expected to complete within 90 days.

Value

₹30.00 Cr

Jindal Stainless Acquisition Worth ₹5.08 Cr

Jindal Stainless acquired an additional ~7% stake in Ampin C&I Three, taking its holding to 24.21%. The cash cost is ~₹5.08 crore for a 40 MW captive solar project.

Value

₹5.08 Cr

solar captive capacity

40.0 MW